Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of CKD-349 vs D113 (Entresto) in Healthy Volunteers
NCT04952506Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jul 2021
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CKD-349 in chronic kidney disease (CKD) (6 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Curve to the Last Quantifiable Concentration and Maximum Plasma Concentration. Started Jul 2021; status: completed.
02
Drugs
CKD-349
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT04952506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04952506.